6 European Projects Found
Searched on 125080 European Projects
FINISHED
Collaborative Oncological Gene-environment Study (COGS)
Start date: May 1, 2009, End date: Jan 31, 2014,
The overarching goal of COGS is to identify individuals with an increased risk of breast, ovary and prostate cancer. Furthermore, we will evaluate the effect of inherited genetic variation on tumour characteristics and clinical outcome. We will do this through quantifying the role of genetic and environmental/lifestyle risk in the largest data set ever generated. In all, we will include over 200,0 ...
Read Project
16
Partners Participants
FINISHED
Prediction of bladder cancer disease course using risk scores that combine molecular and clinical risk factors (UROMOL)
Start date: Feb 1, 2008, End date: Jul 31, 2013,
"Bladder cancer is a recurrent and very prevalent cancer and it generates the highest cost per patient in Europe. New genomic methods have allowed identifying new markers with potential clinical application. However, due to the use of single-marker assays and poor study design, none of these markers has made it to the clinic. FGFR3 and PIK3CA mutations, expression profiles, and microsatellite alte ...
Read Project
8
Partners Participants
FINISHED
Novel MS-based strategies to Discover and Evaluate Cancer Biomarkers in urine: Application to Diagnosis of Bladder Cancer (DECanBio)
Start date: Mar 1, 2008, End date: Jul 31, 2012,
In clinical studies, proteomics and transcriptomics allow the comparison of samples from different patients and hold special promise for the discovery of novel biomarkers and the development of “personalized medicine” approaches. Yet, translating recent discoveries into daily medical practice takes time and despite intensified researchers’ interest and investments, the rate of introduction of nove ...
Read Project
9
Partners Participants
FINISHED
The use of Methylated DNA Immunoprecipitation MeDIP in cancer for better clinical management (CANCERDIP)
Start date: Jan 1, 2008, End date: Jun 30, 2011,
"Aberrant DNA methylation is the most common molecular lesion of the cancer cell. Neither gene mutation nor cytogenetic abnormalities are as common in human tumours as DNA methylation alterations. The stability of our genome and correct gene expression is maintained to a great extent thanks to a perfectly preestablished pattern of DNA methylation and histone modifications. In cancer this idealisti ...
Read Project
7
Partners Participants
FINISHED
Identification and characterization of novel human telomere-related biomarkers that aid cancer management by improving patient diagnosis, treatment selection, response monitoring, and drug development (TeloMarker)
Start date: Feb 1, 2008, End date: Jan 31, 2011,
Telomeres are DNA-nucleoprotein structures that protect the ends of human chromosomes through the formation of a ‘cap’ that prevents exonucleolytic degradation, inter- & intra-chromosomal fusion and subsequent chromosomal instability. Telomerase, the ribonucleoprotein enzyme that maintains linear chromosomal DNA ends by the addition of TTAGGG repeats, is completely repressed or present only at low ...
Read Project
8
Partners Participants
FINISHED
Genomic Instability in Cancer and Precancer (GENICA)
Start date: Jan 1, 2008, End date: Dec 31, 2010,
"Genomic instability is a characteristic of practically all human cancers. Recent results generated by members of this Consortium suggest that signs of genomic instability are evident from the very beginning of human cancer development, even in precancerous lesions. In these early lesions, the genomic instability affects primarily specific genomic loci, called common fragile sites. Because common ...
Read Project
